57183-50-3

Usage

InChI:InChI=1/C16H13NO2/c1-19-12-7-8-14-13(9-12)16(18)10-15(17-14)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)

Upstream product

• 93663-71-9 ethyl 6-methoxy-4-oxo-2-phenyl-1,4-dihydroquinoline-3-carboxylate 
• 6342-63-8 1-(2-bromo-5-methoxyphenyl)ethanone 
• 55-21-0 benzamide 
• 1256842-39-3 ethyl 3-cyano-3-(4-methoxyphenylamino)-3-phenylpropanoate 
• 104-94-9 4-methoxy-aniline 
• 94-02-0 ethyl 3-oxo-3-phenylpropionate 
• 106536-15-6 ethyl 3-chloro-2-(ethoxycarbonyl)-3-phenyl-propenoate 
• 828264-17-1 2-[(4-methoxy-phenylamino)-phenyl-methylene]-malonic acid diethyl ester 
• 57183-43-4 ethyl 3-(4-methoxyphenylamino)-3-phenylacrylate 

Downstream Products

• 35673-25-7 6-methoxy-2-phenyl-4H-benzo[d][1,3]oxazin-4-one 
• 147779-39-3 2-benzoylamino-5-methoxy-benzoic acid 
• 147197-84-0 6-hydroxy-2-phenylquinolin-4(1H)-one 
• 50593-72-1 4-chloro-6-methoxy-2-phenylquinoline 
• 18617-96-4 2-Phenyl-4-merapto-6-methoxychinolin 
• 1233355-53-7 LDN-209964 
• 867017-08-1 4-(4-acetyl phenyl amino)-6-methoxy-2-phenylquinoline 
• 867017-09-2 1-[3-(6-methoxy-2-phenyl-quinolin-4-ylamino)-phenyl]-ethanone 

Relevant academic research and scientific papers

ACRIDINES AS INHIBITORS OF HASPIN AND DYRK KINASES

The present disclosure is directed to compounds of Formula I: which are inhibitors of Haspin kinase and DYRK kinases. The compounds of the present disclosure, and compositions thereof, are useful in the treatment of disease related to Haspin kinase and DY

Structure-activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors

Haspin is a serine/threonine kinase required for completion of normal mitosis that is highly expressed during cell proliferation, including in a number of neoplasms. Consequently, it has emerged as a potential therapeutic target in oncology. A high throughput screen of approximately 140,000 compounds identified an acridine analog as a potent haspin kinase inhibitor. Profiling against a panel of 270 kinases revealed that the compound also exhibited potent inhibitory activity for DYRK2, another serine/threonine kinase. An optimization study of the acridine series revealed that the structure-activity relationship (SAR) of the acridine series for haspin and DYRK2 inhibition had many similarities. However, several structural differences were noted that allowed generation of a potent haspin kinase inhibitor (33, IC50 50 400 nM) with a 5.4-fold selectivity over haspin was also identified.

Microwave-assisted synthesis of polysubstituted 4-quinolones from deprotonated α-aminonitriles

The α-alkylation of deprotonated N-aryl-α-aminonitriles with α-bromoesters furnishes intermediates that can be cyclized to 4-quinolones upon microwave irradiation. Alternatively, base-induced dehydrocyanation of the alkylation products furnishes enaminoes

Synthesis and cytotoxic evaluation of certain 4-anilino-2-phenylquinoline derivatives

The present report describes the synthesis and cell growth inhibition of certain 4-anilino-2-phenylquinoline derivatives. 4-(4-Acetylphenylamino)-6- methoxy-2-phenylquinoline (11), its oxime 15a, and its methyloxime 15b, exhibited significant cytotoxicity

Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: Identification as antimitotic agents interacting with tubulin

A series of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds have been synthesized and evaluated as cytotoxic compounds and as antimitotic agents interacting with tubulin. The 2-phenyl-4-quinolones (22-30) with substituents